Paul Marshall and Ian Wace’s Top 5 Stock Picks

view original post

In this article, we discuss the Paul Marshall and Ian Wace’s top 5 stock picks. If you want to read our detailed analysis of Marshall and Wace’s history, investment philosophy, and hedge fund performance, go directly to Paul Marshall and Ian Wace’s 10 Stock Picks: Biogen Inc (BIIB) Apple Inc (AAPL) and More

5. Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)

Marshall and Wace’s Stake Value: $265,259,000
Percentage of Paul Marshall and Ian Wace’s 13F Portfolio: 1.19%
Number of Hedge Fund Holders: 27 

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) is a biopharmaceutical company that develops medicines for neurological illnesses and uncommon conditions. The company was established in 2013 and is placed fifth on the list of Paul Marshall and Ian Wace’s stock picks.

On September 13, Cantor Fitzgerald analyst Charles Duncan raised his price target on Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) to $165 from $151 and reiterated an “Overweight” rating on the shares. On August 9, Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) posted earnings for the second quarter of 2021. It reported earnings per share of -$2.62, missing the predictions by $0.38. Revenue over the period was $92.9 million, up 858.7% YoY, beating the estimates by $7.05 million. 

Paul Marshall and Ian Wace’s Marshall Wace LLP currently owns 2.73 million shares of Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) worth $265.26 million. Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) occupies 1.19% of Marshall Wace LLP’s overall equity. In addition, there were 27 hedge funds in our database that held stakes in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) in the second quarter 2021, compared to 33 funds in the previous quarter. 

Baron Funds, in its first-quarter 2021 investor letter, mentioned Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN). Here is what the fund said: 

“Biohaven Pharmaceutical Holding Company Ltd. is a biotechnology company dedicated to neurologic drug discovery. It launched its lead asset, migraine medication Nurtec, last year, and the company is transitioning towards profitability. Shares declined when Biohaven issued a secondary offering in March that took investors by surprise and seemed early in relation to an expected second indication for Nurtec in the prophylactic prevention of migraine, which expands its market. We exited our position.”